GBR 1302, a HER2x CD3 bispecific antibody, is the first clinical candidate based on Glenmark’s proprietary best-in-class BEAT® platform.
Sedating antihistamines mechanism of action
Evidence does not support the use of mite-proof impermeable covers, air filtration systems, or delayed exposure to solid foods in infancy.
Allergic rhinitis is an immunoglobulin E–mediated disease, thought to occur after exposure to indoor and outdoor allergens such as dust mites, insects, animal danders, molds, and pollens.
GBR 1342, a CD38x CD3 bispecific antibody based on Glenmark’s proprietary BEAT® platform.
It targets CD38, a proven target in multiple myeloma.
SUR, MD, and STEPHANIE SCANDALE, MD, David Geffen School of Medicine, University of California, Los Angeles, California Am Fam Physician. A more recent article on allergic rhinitis is available.
Allergic rhinitis is a common chronic respiratory illness that affects quality of life, productivity, and other comorbid conditions, including asthma.
Glenmark plans to file an Investigational New Drug (IND) application to initiate a Phase 1 study in the second half of CY 2017.
New treatments have improved the survival rate in multiple myeloma patients, but the disease remains incurable.
Allergic rhinitis is a common and chronic immunoglobulin E–mediated respiratory illness that can affect quality of life and productivity, as well as exacerbate other conditions such as asthma.